Register Login

All Posts

11-8-25 AHA Presentation Records Successful Reduction of Anticoagulation in AFIB

Click here for the results of a “One month of clot prevention after a stent was as effective as a Year-long course for AFIB.” Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received […]
read more

An Illustrated Review of Hemophilia B.

Click here for the illustrated open-access review, Hermans C, Astermark J, Trakymienė SŠ, Jiménez-Yuste, V. Haemophilia B: an illustrative review of current challenges and opportunities.  Res Prac Thromb Haemostasis, 2025;9, 103229. Abstract Background Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. […]
read more

VWF Factor Assays in Caplacizumab Therapy

Check with your medical library or join ISTH to obtain Colpani P, Baronciani L, Mancini I, et al. Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction. J Thromb Haemost. 2025:S1538-7836(25)00545-8. doi: 10.1016/j.jtha.2025.08.020. PMID: 40915571. Abstract Background: Caplacizumab, a humanized […]
read more

Viewpoint: Anticoagulation for Climate Resilient Care

Go to your medical library to obtain Fan BE, Milla K, McAlister S, et al, Sustainable anticoagulation for climate resilient care. Lancet Haematol. 2025;12:e918-e925. doi: 10.1016/S2352-3026(25)00204-2.  PMID: 40972616. Abstract This Viewpoint issues a multidisciplinary call to embed sustainability into anticoagulation care, aligning clinical excellence with climate responsibility. Anticoagulation management-including drug manufacturing, laboratory diagnostics, therapeutic monitoring, […]
read more